Reviva Pharmaceuticals (NASDAQ:RVPH) Earns “Buy” Rating from D. Boral Capital

Reviva Pharmaceuticals (NASDAQ:RVPH)‘s stock had its “buy” rating reaffirmed by D. Boral Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $2.00 price objective on the stock. D. Boral Capital’s price target suggests a potential upside of 238.98% from the stock’s current price.

Several other equities analysts also recently weighed in on the company. Chardan Capital upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, November 19th. Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research note on Wednesday, October 8th. Benchmark dropped their target price on shares of Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating on the stock in a research note on Monday, September 15th. Wall Street Zen raised shares of Reviva Pharmaceuticals to a “sell” rating in a research report on Saturday, October 4th. Finally, HC Wainwright decreased their price objective on shares of Reviva Pharmaceuticals from $11.00 to $4.00 and set a “buy” rating for the company in a report on Monday, October 27th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Reviva Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $3.86.

Reviva Pharmaceuticals Stock Performance

RVPH stock opened at $0.59 on Tuesday. The firm has a 50 day moving average price of $0.57 and a 200-day moving average price of $0.52. Reviva Pharmaceuticals has a 52-week low of $0.25 and a 52-week high of $2.17. The firm has a market capitalization of $67.89 million, a price-to-earnings ratio of -1.28 and a beta of -0.02.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.05. As a group, sell-side analysts forecast that Reviva Pharmaceuticals will post -0.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RVPH. XTX Topco Ltd purchased a new stake in Reviva Pharmaceuticals in the second quarter worth approximately $31,000. Lido Advisors LLC bought a new position in shares of Reviva Pharmaceuticals during the 3rd quarter valued at $37,000. NewEdge Advisors LLC purchased a new position in shares of Reviva Pharmaceuticals in the 1st quarter worth $58,000. Geode Capital Management LLC grew its holdings in shares of Reviva Pharmaceuticals by 6.9% in the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after acquiring an additional 29,063 shares during the period. Finally, Persistent Asset Partners Ltd increased its position in Reviva Pharmaceuticals by 300.0% during the second quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock valued at $244,000 after acquiring an additional 480,864 shares during the last quarter. Institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.